Shaarawy T, Nguyen C, Schnyder C, Mermoud A
Department of Ophthalmology, Hôpital Ophtalmique Jules Gonin, University of Lausanne, Avenue de France 15, CH-1004 Lausanne, Switzerland.
Br J Ophthalmol. 2004 Jan;88(1):95-8. doi: 10.1136/bjo.88.1.95.
To identify the value of using collagen implant in deep sclerectomy.
A prospective randomised trial of 104 eyes (104 patients) with medically uncontrolled primary and secondary open angle glaucoma. All patients had deep sclerectomy (DS), half of them with and the other half without a collagen implant (CI) sutured in the scleral bed. The main outcome measures were intraocular pressure (IOP), visual acuity, number of treatments preoperative and postoperative, and Nd:YAG goniopunctures.
Mean follow up period was 44.5 (SD 21) months for the DS group and 43.9 (SD 14) months for the deep sclerectomy with a collagen implant (DSCI) group. The mean preoperative IOP was 23.3 (SD 7.2) mm Hg for the DS group and 25.6 (SD 4.9) mm Hg for the DSCI group. The mean IOP at the first postoperative day was 6.1 (SD 4.21) mm Hg for the DS group and 5.1 (SD 3.3) mm Hg for the DSCI group. At 48 months IOP was reduced by 40% (14 versus 23.3 mm Hg) for the DS group and by 50% (12.7 versus 25.6 mm Hg) for the DSCI group. Complete success rate, defined as IOP lower than 21 mm Hg without medication, was 34.6% (18/52 patients) at 48 months for the DS group, and 63.4% (33/52 patients) for the DSCI group. Qualified success rate; patients who achieved IOP below 21 mm Hg with or without medication, was 78.8% (41/52 patients) at 48 months and 94% (49/52 patients) for the DSCI group. The mean number of medications was reduced from 2.1 (SD 0.8) to 1.0 (SD 1) after DS, and was reduced from 2.2 (SD 0.7) to 0.4 (SD 0.6) in the DSCI group (p = 0.001)
The use of a collagen implant in DS enhances the success rates and lowers the need for postoperative medication.
确定在深层巩膜切除术中使用胶原植入物的价值。
对104例(104只眼)药物治疗无法控制的原发性和继发性开角型青光眼患者进行前瞻性随机试验。所有患者均接受深层巩膜切除术(DS),其中一半在巩膜床缝合胶原植入物(CI),另一半未缝合。主要观察指标为眼压(IOP)、视力、术前和术后治疗次数以及钕:钇铝石榴石激光小梁穿刺术。
DS组平均随访期为44.5(标准差21)个月,胶原植入物深层巩膜切除术(DSCI)组为43.9(标准差14)个月。DS组术前平均IOP为23.3(标准差7.2)mmHg,DSCI组为25.6(标准差4.9)mmHg。DS组术后第1天平均IOP为6.1(标准差4.21)mmHg,DSCI组为5.1(标准差3.3)mmHg。48个月时,DS组IOP降低40%(从23.3 mmHg降至14 mmHg),DSCI组降低50%(从25.6 mmHg降至12.7 mmHg)。完全成功率定义为无需药物治疗眼压低于21 mmHg,DS组48个月时为34.6%(18/52例患者),DSCI组为63.4%(33/52例患者)。合格成功率;无论是否用药眼压低于21 mmHg的患者,DS组48个月时为78.8%(41/52例患者),DSCI组为94%(49/52例患者)。DS术后平均用药次数从2.1(标准差0.8)降至1.0(标准差1),DSCI组从2.2(标准差0.7)降至0.4(标准差0.6)(p = 0.001)
在DS中使用胶原植入物可提高成功率并减少术后用药需求。